NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 3.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 237,762 shares of the medical research company’s stock after selling 8,050 shares during the period. Parkman Healthcare Partners LLC owned 0.19% of NeoGenomics worth $3,847,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Quadrant Capital Group LLC lifted its holdings in shares of NeoGenomics by 22.0% in the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after acquiring an additional 883 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of NeoGenomics by 7.0% in the fourth quarter. Handelsbanken Fonder AB now owns 19,900 shares of the medical research company’s stock valued at $322,000 after buying an additional 1,300 shares in the last quarter. Yousif Capital Management LLC raised its holdings in shares of NeoGenomics by 2.6% in the 4th quarter. Yousif Capital Management LLC now owns 65,447 shares of the medical research company’s stock valued at $1,059,000 after buying an additional 1,654 shares during the period. Swiss National Bank boosted its holdings in NeoGenomics by 1.0% during the 3rd quarter. Swiss National Bank now owns 280,400 shares of the medical research company’s stock valued at $3,449,000 after acquiring an additional 2,700 shares during the period. Finally, Burkett Financial Services LLC acquired a new position in NeoGenomics in the 4th quarter valued at about $46,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Stock Down 4.6 %

Shares of NeoGenomics stock traded down $0.64 during trading hours on Thursday, hitting $13.42. The company had a trading volume of 737,799 shares, compared to its average volume of 861,318. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 7.22. The company’s 50-day moving average is $14.31 and its two-hundred day moving average is $15.66. The company has a market cap of $1.71 billion, a P/E ratio of -20.33 and a beta of 1.17. NeoGenomics, Inc. has a twelve month low of $11.03 and a twelve month high of $21.22.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $156.24 million during the quarter, compared to analyst estimates of $149.82 million. NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. Analysts anticipate that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NEO has been the subject of a number of research reports. The Goldman Sachs Group lifted their price objective on shares of NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Craig Hallum started coverage on NeoGenomics in a research note on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price objective on the stock. BTIG Research lowered their target price on NeoGenomics from $23.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Finally, Benchmark reissued a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.78.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.